BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nwaohiri A, Schillie S, Bulterys M, Kourtis AP. Hepatitis C virus infection in children: How do we prevent it and how do we treat it? Expert Rev Anti Infect Ther 2018;16:689-94. [PMID: 30091654 DOI: 10.1080/14787210.2018.1509707] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R, Mittal N, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Narkewicz MR, Rao GS, Whitworth S, Bansal S, Balistreri WF. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology 2020;71:422-30. [PMID: 31220349 DOI: 10.1002/hep.30830] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 18.0] [Reference Citation Analysis]
2 Ward JW, Hinman AR. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology. 2019;156:297-310. [PMID: 30391470 DOI: 10.1053/j.gastro.2018.10.048] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
3 Kamal EM, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, Attia D. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver Int. 2020;40:319-323. [PMID: 31758735 DOI: 10.1111/liv.14308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
4 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 El-Shabrawi M, Baroudy S, Hassanin F, Behairy AS, Yakoot M, Ahmed A. Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country. Acta Paediatr 2020;109:2699-705. [PMID: 32358871 DOI: 10.1111/apa.15333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li M, Zhuang H, Wei L. How would China achieve WHO's target of eliminating HCV by 2030? Expert Rev Anti Infect Ther 2019;17:763-73. [PMID: 31578079 DOI: 10.1080/14787210.2019.1675509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
7 Auriti C, De Rose DU, Santisi A, Martini L, Piersigilli F, Bersani I, Ronchetti MP, Caforio L. Pregnancy and viral infections: Mechanisms of fetal damage, diagnosis and prevention of neonatal adverse outcomes from cytomegalovirus to SARS-CoV-2 and Zika virus. Biochim Biophys Acta Mol Basis Dis 2021;1867:166198. [PMID: 34118406 DOI: 10.1016/j.bbadis.2021.166198] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
8 Lee Y, Park J, Min M, Lee Y, Yu Y, Shim MK, Kim MG. Gender Equity and Vertically Transmitted Infections: A Country-Level Analysis Across 153 Countries. Health Equity 2021;5:23-9. [PMID: 33564737 DOI: 10.1089/heq.2020.0097] [Reference Citation Analysis]
9 Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep. 2020;69:1-17. [PMID: 32271723 DOI: 10.15585/mmwr.rr6902a1] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 44.5] [Reference Citation Analysis]
10 Ragusa R, Corsaro LS, Frazzetto E, Bertino E, Bellia MA, Bertino G. Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. AJP Rep 2020;10:e121-7. [PMID: 32257593 DOI: 10.1055/s-0040-1709185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
11 Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S, Balistreri WF, Bansal S, Jonas MM, Massetto B, Brainard DM, Hsueh CH, Shao J, Parhy B, Davison S, Feiterna-Sperling C, Gillis LA, Indolfi G, Sokal EM, Murray KF, Wirth S. Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. Hepatology 2020;71:31-43. [PMID: 31222783 DOI: 10.1002/hep.30821] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 16.0] [Reference Citation Analysis]
12 Dhiman RK, Grover GS, Premkumar M. Hepatitis C elimination: a Public Health Perspective. Curr Treat Options Gastro 2019;17:367-77. [DOI: 10.1007/s11938-019-00240-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
13 Lens S, Lazarus JV. The paediatric population: the forgotten element to eliminating hepatitis C virus. Lancet Gastroenterol Hepatol 2020;5:334-5. [PMID: 31954440 DOI: 10.1016/S2468-1253(19)30405-4] [Reference Citation Analysis]
14 Alqahtani SA, Colombo MG. Treating paediatric hepatitis C in the era of direct-acting antiviral agents. Liver Int 2021;41:1189-200. [PMID: 33533543 DOI: 10.1111/liv.14810] [Reference Citation Analysis]
15 Jaiswal SR, Bhakuni P, Soni M, Gupta M, Thatai A, Chakrabarti S. Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. Transpl Infect Dis 2021;23. [DOI: 10.1111/tid.13490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]